We conducted a prospective, phase 1 trial evaluating the safety and tolerability of the vitamin D receptor agonist paricalcitol given with first-line gemcitabine and albumin-bound paclitaxel in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results